Access to supportive care also plays an important role in outcomes, such as the use of granulocyte colony-stimulating factors has shown to be highly effective in shortening the duration of chemotherapy-induced neutropenia, which is associated with a 20%–25% reduction in the incidence of febrile neutropenia. This evidence concerns the gene CSF2 and neutropenia.